论文部分内容阅读
IL-6是一种重要的细胞因子,在类风湿关节炎发病过程中发挥重要作用。本文对已上市的IL-6受体单克隆抗体tocilizumab对类风湿关节炎的临床疗效和安全性进行了总结,并和TNF-α阻断药物进行了对比,证明tocilizumab在药物疗效和副作用方面与TNF-α阻断药物相比各有优劣。另外也对在研的IL-6通路阻断单抗的临床试验结果进行了总结。结合本中心近年的研究和总结,IL-6是继TNF-α之后的另一个重要的类风湿关节炎治疗关键靶点,该类药物的上市为以后类风湿关节炎的个性化治疗提供了更多的选择。
IL-6 is an important cytokine that plays an important role in the pathogenesis of rheumatoid arthritis. In this paper, the clinical efficacy and safety of the listed monoclonal antibody tocilizumab, an IL-6 receptor, on rheumatoid arthritis were summarized and compared with that of TNF-α blocking drugs. It is demonstrated that tocilizumab is effective in the treatment of side effects There are advantages and disadvantages of TNF-α blocking drugs. In addition, the results of clinical trials of IL-6 blockade monoclonal antibodies under investigation are also summarized. In combination with the recent research and summary of our center, IL-6 is another key therapeutic target of rheumatoid arthritis after TNF-α, and the listing of these drugs will provide more personalized treatment for rheumatoid arthritis later Many choices.